Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny patients, big challenge: new malaria pill for newborns

NCT ID NCT04300309

Summary

This study tested a new, easy-to-swallow tablet version of a common malaria medicine (artemether-lumefantrine) for the smallest patients: babies and newborns weighing less than 11 pounds. The goal was to see if the right amount of medicine gets into their bodies, if it's safe for them, and if it effectively clears the malaria parasite. The study included two groups of very young infants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM MALARIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Novartis Investigative Site

    Nanoro, Burkina Faso

  • Novartis Investigative Site

    Ouagadougou, Burkina Faso

  • Novartis Investigative Site

    Kisantu, Bas Kongo, Democratic Republic of the Congo

Conditions

Explore the condition pages connected to this study.